Cargando…
Peripheral Markers of Depression
Major Depressive Disorder (MDD) is a leading cause of disability worldwide, creating a high medical and socioeconomic burden. There is a growing interest in the biological underpinnings of depression, which are reflected by altered levels of biological markers. Among others, enhanced inflammation ha...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7760788/ https://www.ncbi.nlm.nih.gov/pubmed/33255237 http://dx.doi.org/10.3390/jcm9123793 |
_version_ | 1783627415733403648 |
---|---|
author | Nobis, Aleksander Zalewski, Daniel Waszkiewicz, Napoleon |
author_facet | Nobis, Aleksander Zalewski, Daniel Waszkiewicz, Napoleon |
author_sort | Nobis, Aleksander |
collection | PubMed |
description | Major Depressive Disorder (MDD) is a leading cause of disability worldwide, creating a high medical and socioeconomic burden. There is a growing interest in the biological underpinnings of depression, which are reflected by altered levels of biological markers. Among others, enhanced inflammation has been reported in MDD, as reflected by increased concentrations of inflammatory markers—C-reactive protein, interleukin-6, tumor necrosis factor-α and soluble interleukin-2 receptor. Oxidative and nitrosative stress also plays a role in the pathophysiology of MDD. Notably, increased levels of lipid peroxidation markers are characteristic of MDD. Dysregulation of the stress axis, along with increased cortisol levels, have also been reported in MDD. Alterations in growth factors, with a significant decrease in brain-derived neurotrophic factor and an increase in fibroblast growth factor-2 and insulin-like growth factor-1 concentrations have also been found in MDD. Finally, kynurenine metabolites, increased glutamate and decreased total cholesterol also hold promise as reliable biomarkers for MDD. Research in the field of MDD biomarkers is hindered by insufficient understanding of MDD etiopathogenesis, substantial heterogeneity of the disorder, common co-morbidities and low specificity of biomarkers. The construction of biomarker panels and their evaluation with use of new technologies may have the potential to overcome the above mentioned obstacles. |
format | Online Article Text |
id | pubmed-7760788 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-77607882020-12-26 Peripheral Markers of Depression Nobis, Aleksander Zalewski, Daniel Waszkiewicz, Napoleon J Clin Med Review Major Depressive Disorder (MDD) is a leading cause of disability worldwide, creating a high medical and socioeconomic burden. There is a growing interest in the biological underpinnings of depression, which are reflected by altered levels of biological markers. Among others, enhanced inflammation has been reported in MDD, as reflected by increased concentrations of inflammatory markers—C-reactive protein, interleukin-6, tumor necrosis factor-α and soluble interleukin-2 receptor. Oxidative and nitrosative stress also plays a role in the pathophysiology of MDD. Notably, increased levels of lipid peroxidation markers are characteristic of MDD. Dysregulation of the stress axis, along with increased cortisol levels, have also been reported in MDD. Alterations in growth factors, with a significant decrease in brain-derived neurotrophic factor and an increase in fibroblast growth factor-2 and insulin-like growth factor-1 concentrations have also been found in MDD. Finally, kynurenine metabolites, increased glutamate and decreased total cholesterol also hold promise as reliable biomarkers for MDD. Research in the field of MDD biomarkers is hindered by insufficient understanding of MDD etiopathogenesis, substantial heterogeneity of the disorder, common co-morbidities and low specificity of biomarkers. The construction of biomarker panels and their evaluation with use of new technologies may have the potential to overcome the above mentioned obstacles. MDPI 2020-11-24 /pmc/articles/PMC7760788/ /pubmed/33255237 http://dx.doi.org/10.3390/jcm9123793 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Nobis, Aleksander Zalewski, Daniel Waszkiewicz, Napoleon Peripheral Markers of Depression |
title | Peripheral Markers of Depression |
title_full | Peripheral Markers of Depression |
title_fullStr | Peripheral Markers of Depression |
title_full_unstemmed | Peripheral Markers of Depression |
title_short | Peripheral Markers of Depression |
title_sort | peripheral markers of depression |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7760788/ https://www.ncbi.nlm.nih.gov/pubmed/33255237 http://dx.doi.org/10.3390/jcm9123793 |
work_keys_str_mv | AT nobisaleksander peripheralmarkersofdepression AT zalewskidaniel peripheralmarkersofdepression AT waszkiewicznapoleon peripheralmarkersofdepression |